T
TXG icon

Transce3nd’s 10x Genomics TXG Stock Holding History

Transce3nd’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-44
Closed -$5.19K – 181
2025
Q3 		$5.19K Sell
44
-63
-59% -$821 0.05% 100
2025
Q2 		$1.29K Hold
107
– – ﹤0.01% 945
2025
Q1 		$888 Sell
107
-58
-35% -$731 ﹤0.01% 971
2024
Q4 		$2.4K Buy
+165
New +$2.6K ﹤0.01% 1082

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Transce3nd's TXG Position: Q4 2025 in Review

Transce3nd sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 44 shares — an estimated $5.19K sold.

Transce3nd first reported a position in TXG in Q4 2024 and held it in 4 quarters. The position peaked at $5.19K in Q3 2025. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Transce3nd reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • Transce3nd sold 44 10x Genomics shares in Q4 2025, an estimated $5.19K.
  • Transce3nd first reported a position in 10x Genomics in Q4 2024 and held it in 4 quarters.
  • Transce3nd's 10x Genomics position peaked at $5.19K in Q3 2025.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Transce3nd's 13F filing for Q4 2025, filed 6 Feb 2026.